Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBITDA: 2009-2025

Historic EBITDA for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$594,147.

  • China Pharma Holdings' EBITDA rose 39.39% to -$594,147 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 27.27%. This contributed to the annual value of -$4.9 million for FY2024, which is 52.16% down from last year.
  • Per China Pharma Holdings' latest filing, its EBITDA stood at -$594,147 for Q3 2025, which was down 16.93% from -$508,104 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' EBITDA peaked at -$270,654 during Q1 2023, and registered a low of -$1.5 million during Q2 2022.
  • For the 3-year period, China Pharma Holdings' EBITDA averaged around -$904,447, with its median value being -$977,467 (2024).
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 3,502.33% in 2021, then skyrocketed by 72.32% in 2023.
  • China Pharma Holdings' EBITDA (Quarterly) stood at -$836,967 in 2021, then dropped by 29.12% to -$1.1 million in 2022, then declined by 2.37% to -$1.1 million in 2023, then fell by 29.03% to -$1.4 million in 2024, then skyrocketed by 39.39% to -$594,147 in 2025.
  • Its EBITDA was -$594,147 in Q3 2025, compared to -$508,104 in Q2 2025 and -$778,056 in Q1 2025.